X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (30) 30
oncology (28) 28
female (25) 25
male (24) 24
middle aged (24) 24
aged (22) 22
index medicus (21) 21
adult (18) 18
aged, 80 and over (16) 16
chemotherapy (14) 14
neoplasms - drug therapy (14) 14
antineoplastic agents - adverse effects (10) 10
antineoplastic combined chemotherapy protocols - therapeutic use (10) 10
article (10) 10
antineoplastic combined chemotherapy protocols - adverse effects (9) 9
capecitabine (9) 9
deoxycytidine - analogs & derivatives (9) 9
maximum tolerated dose (9) 9
pharmacology & pharmacy (9) 9
cancer (8) 8
dose-response relationship, drug (8) 8
pharmacology/toxicology (8) 8
treatment outcome (8) 8
antineoplastic agents - administration & dosage (7) 7
antineoplastic agents - therapeutic use (7) 7
deoxycytidine - administration & dosage (7) 7
fluorouracil (7) 7
fluorouracil - administration & dosage (7) 7
medicine & public health (7) 7
antineoplastic agents - pharmacokinetics (6) 6
fluorouracil - analogs & derivatives (6) 6
neoplasms - complications (6) 6
trial (6) 6
1st-line treatment (5) 5
clinical trials (5) 5
colorectal cancer (5) 5
deoxycytidine - adverse effects (5) 5
fluorouracil - adverse effects (5) 5
gemcitabine (5) 5
organoplatinum compounds - administration & dosage (5) 5
organoplatinum compounds - adverse effects (5) 5
oxaliplatin (5) 5
phase i (5) 5
5-fluorouracil (4) 4
adenocarcinoma - drug therapy (4) 4
administration, oral (4) 4
cisplatin (4) 4
drug administration schedule (4) 4
leucovorin (4) 4
pharmacokinetics (4) 4
phase-ii (4) 4
research (4) 4
solid tumors (4) 4
studies (4) 4
united states (4) 4
whole body hyperthermia (4) 4
abridged index medicus (3) 3
antineoplastic combined chemotherapy protocols - administration & dosage (3) 3
antineoplastic combined chemotherapy protocols - pharmacokinetics (3) 3
cancer research (3) 3
care and treatment (3) 3
colorectal neoplasms - drug therapy (3) 3
combination (3) 3
complications and side effects (3) 3
deoxycytidine - therapeutic use (3) 3
dosage and administration (3) 3
drug therapy (3) 3
infusions, intravenous (3) 3
irinotecan (3) 3
kidney diseases - metabolism (3) 3
kras (3) 3
leucovorin - administration & dosage (3) 3
neoplasm staging (3) 3
neoplasms - metabolism (3) 3
of-life care (3) 3
organoplatinum compounds - pharmacokinetics (3) 3
organoplatinum compounds - therapeutic use (3) 3
palliative care (3) 3
pancreatic cancer (3) 3
pancreatic neoplasms - drug therapy (3) 3
panitumumab (3) 3
pharmaceutical sciences (3) 3
platinum (3) 3
pyrimidines - adverse effects (3) 3
pyrimidines - pharmacokinetics (3) 3
ras mutations (3) 3
sorafenib (3) 3
survival (3) 3
survival analysis (3) 3
therapy (3) 3
tyrosine kinase inhibitor (3) 3
usage (3) 3
angiogenesis inhibitors - adverse effects (2) 2
angiogenesis inhibitors - therapeutic use (2) 2
antineoplastic agents - pharmacology (2) 2
benzamides (2) 2
bevacizumab (2) 2
bile duct cancer (2) 2
boronic acids - administration & dosage (2) 2
boronic acids - pharmacokinetics (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


JAMA, ISSN 0098-7484, 06/2017, Volume 317, Issue 23, pp. 2392 - 2401
IMPORTANCE: Combining biologic monoclonal antibodies with chemotherapeutic cytotoxic drugs provides clinical benefit to patients with advanced or metastatic... 
Leucovorin - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Bevacizumab - therapeutic use | United States | Bevacizumab - adverse effects | Colorectal Neoplasms - genetics | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Antineoplastic Agents - therapeutic use | Cetuximab - therapeutic use | Cetuximab - adverse effects | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Leucovorin - adverse effects | Fluorouracil - adverse effects | Antineoplastic Agents - adverse effects | Colorectal Neoplasms - drug therapy | Aged, 80 and over | Angiogenesis Inhibitors - therapeutic use | Adult | Camptothecin - administration & dosage | Female | Angiogenesis Inhibitors - adverse effects | Camptothecin - analogs & derivatives | Colorectal Neoplasms - mortality | Camptothecin - adverse effects | Kaplan-Meier Estimate | Treatment Outcome | Canada | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Colorectal Neoplasms - secondary | Aged | Genes, ras | Organoplatinum Compounds - adverse effects | MEDICINE, GENERAL & INTERNAL | LEUCOVORIN | FIRE-3 | THERAPY | FOLFIRI PLUS CETUXIMAB | PHASE-II | IRINOTECAN | OXALIPLATIN | FLUOROURACIL | TUMORS | PROGRESSION | Chemotherapy | Usage | Care and treatment | Research | Colorectal cancer | Cancer | Drugs | Medical research | Colorectal carcinoma | Clinical trials | Cytotoxicity | Patients | Survival | K-Ras protein | Bevacizumab | Metastases | Survival analysis | Irinotecan | Randomization | Oxaliplatin | Monoclonal antibodies | Tumors
Journal Article
Journal Article
Investigational New Drugs, ISSN 0167-6997, 4/2016, Volume 34, Issue 2, pp. 168 - 175
Background KRAS mutations are clinically important predictors of resistance to EGFR-directed therapies in colorectal cancer (CRC). Oncogenic activation of the... 
Selumetinib | Phase I | Colon cancer | Medicine & Public Health | AZD6244 | Oncology | KRAS | Pharmacology/Toxicology | Cetuximab | SURVIVAL | BRAF | PANITUMUMAB | POTENT | ONCOLOGY | PHARMACOLOGY & PHARMACY | MUTATIONS | AZD6244 ARRY-142886 | Proto-Oncogene Proteins p21(ras) - genetics | Colorectal Neoplasms - genetics | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Cetuximab - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Cetuximab - adverse effects | Dose-Response Relationship, Drug | Mitogen-Activated Protein Kinase Kinases - metabolism | Colorectal Neoplasms - drug therapy | Aged, 80 and over | Adult | Female | Benzimidazoles - adverse effects | Benzimidazoles - therapeutic use | Colorectal Neoplasms - blood | Mitogen-Activated Protein Kinase Kinases - antagonists & inhibitors | Benzimidazoles - pharmacokinetics | Cetuximab - pharmacology | Treatment Outcome | Mutation - genetics | Maximum Tolerated Dose | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Benzimidazoles - pharmacology | Aged | Protein Kinase Inhibitors - pharmacology | Complications and side effects | Care and treatment | Usage | Gene mutations | Analysis | Colorectal cancer | Clinical trials | Genetic aspects | Studies | Inhibitor drugs | Pharmaceutical sciences | Index Medicus | cetuximab | phase I | selumetinib | colon cancer
Journal Article
The Oncologist, ISSN 1083-7159, 07/2016, Volume 21, Issue 7, pp. 785 - 786g
作者总结 经验 • 在临床试验中, 应该将胰腺神经内分泌瘤与类癌分开进行研究。 • 在低级别神经内分泌瘤的II期临床试验中, 无进展生存作为主要终点 (比缓解率) 更具有临床相关性。 摘要 背景 . 神经内分泌瘤 (NET) 最常见的亚型是胰岛细胞肿瘤和类癌,... 
CAPECITABINE | SOLID TUMORS | ONCOLOGY | CYCLE ARREST | NOTCH | LYMPHOMA | VALPROIC ACID | DIFFERENTIATION | CARCINOID CANCER-CELLS | TUMORIGENESIS | TEMOZOLOMIDE | Humans | Middle Aged | Neuroendocrine Tumors - mortality | Aged, 80 and over | Neuroendocrine Tumors - drug therapy | Adult | Female | Hydroxamic Acids - therapeutic use | Indoles - therapeutic use | Male | Aged | Histone Deacetylase Inhibitors - therapeutic use | Index Medicus | Clinical Trial Results
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2008, Volume 26, Issue 4, pp. 563 - 569
Journal Article
Journal Article
JNCCN Journal of the National Comprehensive Cancer Network, ISSN 1540-1405, 01/2018, Volume 16, Issue 1, pp. 99 - 103
Journal Article
JNCCN Journal of the National Comprehensive Cancer Network, ISSN 1540-1405, 12/2018, Volume 16, Issue 12, pp. 1442 - 1450
Background: Molecular profiles guide the clinical management of metastatic colorectal cancer (mCRC), particularly related to the use of anti-epidermal growth... 
PANITUMUMAB | SURVIVAL | 1ST-LINE TREATMENT | GENOMIC LANDSCAPE | SOLID TUMORS | ONCOLOGY | RAS MUTATIONS | CETUXIMAB PLUS IRINOTECAN | PHASE-III | OPEN-LABEL | KRAS
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2008, Volume 26, Issue 4, pp. 570 - 576
Journal Article
Investigational New Drugs, ISSN 0167-6997, 2/2015, Volume 33, Issue 1, pp. 169 - 176
Journal Article
Investigational New Drugs, ISSN 0167-6997, 02/2015, Volume 33, Issue 1, p. 169
  RO4929097 is an oral inhibitor of γ -secretase that results in Notch signaling inhibition. Prior work has demonstrated that Notch signaling inhibition... 
Complications and side effects | Chemotherapy, Combination | Capecitabine | Dosage and administration | Research | Drug therapy | Methods | Tumors | Studies | Clinical trials | Inhibitor drugs | Pharmaceutical sciences | Colorectal cancer
Journal Article
Investigational New Drugs, ISSN 0167-6997, 8/2013, Volume 31, Issue 4, pp. 943 - 948
Chemotherapy has yielded minimal clinical benefit in pancreatic and biliary tract cancer. A high-dose, short course capecitabine schedule with oxaliplatin, has... 
Chemotherapy | Oxaliplatin | Medicine & Public Health | Capecitabine | Pancreatic cancer | Bile duct cancer | Sorafenib | Oncology | Pharmacology/Toxicology | PLUS GEMCITABINE | BAY-43-9006 | SOLID TUMORS | COMBINATION | MULTIKINASE INHIBITOR | TRIAL | HEPATOCELLULAR-CARCINOMA | ONCOLOGY | PHARMACOLOGY & PHARMACY | ERLOTINIB | Niacinamide - analogs & derivatives | Demography | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Antineoplastic Agents - therapeutic use | Dose-Response Relationship, Drug | Pancreatic Neoplasms - drug therapy | Fluorouracil - therapeutic use | Deoxycytidine - therapeutic use | Fluorouracil - adverse effects | Antineoplastic Agents - adverse effects | Phenylurea Compounds - adverse effects | Aged, 80 and over | Adult | Deoxycytidine - adverse effects | Female | Biliary Tract Neoplasms - drug therapy | Wisconsin | Biliary Tract Neoplasms - pathology | Fluorouracil - analogs & derivatives | Pancreatic Neoplasms - pathology | Niacinamide - adverse effects | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Treatment Outcome | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Neoplasm Staging | Organoplatinum Compounds - therapeutic use | Deoxycytidine - analogs & derivatives | Organoplatinum Compounds - adverse effects | Complications and side effects | Dosage and administration | Studies | Research | Drug therapy | Cancer therapies | Pharmaceutical sciences | Index Medicus
Journal Article
The Oncologist, ISSN 1083-7159, 04/2011, Volume 16, Issue 4, pp. 452 - 457
摘要 背景. 低度神经内分泌肿瘤(NET)对化疗反应差,需要一种有效、低毒的疗法。已证明糖原合酶激酶(GSK)‐3β能调节NET的生长和激素分泌。利用氯化锂(LiCl)可以抑制鼠模型中类癌瘤的生长,降低GSK‐3β水平,减少嗜铬粒蛋白A的表达。本研究旨在评价LiCl治疗NET的有效性。 设计.... 
Chemotherapy | Carcinoid tumors | Lithium chloride | Glycogen synthase kinase‐3β | Neuroendocrine tumors | Glycogen synthase kinase-3β | OCTREOTIDE | ISLET-CELL CARCINOMA | DOXORUBICIN | PHASE-II | FLUOROURACIL | ALPHA-INTERFERON | STREPTOZOCIN | 5-FLUOROURACIL | ONCOLOGY | GROWTH | Glycogen synthase kinase-3 beta | Phosphorylation | Lithium Chloride - therapeutic use | Humans | Middle Aged | Lithium Chloride - administration & dosage | Glycogen Synthase Kinase 3 beta | Male | Antineoplastic Agents - therapeutic use | Glycogen Synthase Kinase 3 - metabolism | Disease-Free Survival | Treatment Failure | Neuroendocrine Tumors - drug therapy | Female | Aged | Endocrinology
Journal Article
Journal of oncology practice, 04/2019, p. JOP1800563
The National Comprehensive Cancer Network (NCCN) formed an Infusion Efficiency Workgroup to determine best practices for operating efficient and effective... 
Journal Article
Investigational new drugs, ISSN 0167-6997, 8/2013, Volume 31, Issue 4, pp. 943 - 948
Chemotherapy has yielded minimal clinical benefit in pancreatic and biliary tract cancer. A high-dose, short course capecitabine schedule with oxaliplatin, has... 
capecitabine | oxaliplatin | bile duct cancer | sorafenib | chemotherapy | Pancreatic cancer
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 06/2007, Volume 13, Issue 12, pp. 3623 - 3629
PURPOSE: To assess the maximum tolerated dose (MTD), dose-limiting toxicity (DLT), pharmacodynamics, and antitumor activity of continuous weekly-administered... 
Journal Article